News in a nutshell

No leader at misconduct agency

The Office of Research Integrity hasn’t had a director since the spring of 2009, according to the Report on Research Compliance, a monthly newsletter from Atlantic Information Services. Despite his retirement in September 2009 after being on leave since March 2009, Chris Pascal was still listed as director in July 2010, they report. A spokeswoman for the Department of Health and Human Services, of which ORI is part, issued a short statement in response to the RRC inquiry, saying

Tags: , , , , .

Filed under News in a Nutshell.

6 comments

  1. Dr J Mehrishi, PhD, FRCPath says:

    Because of advances in technology, ‘older’ work has become important for todays problems of great theoretical interest and practical clinical value. During the preparation of MSS, always cautious to check the original publications, looking for some values of parameters, to my horror, I have found grave errors, non-existent data quoted from one paper in others, fictitious values out of nowhere, not in the refs. quoted, no significant difference discovered on inspection, but dramatic claims:
    Js involved: NATURE, The LANCET, BMJ, BLOOD, J CELLULAR BIOLOGY and others!
    The editors/ referees were thoroughly hoodwinked in ‘publishing’ an attractive dramatic result taking decision on their own or by reports on MSS evaluated by referees being buddies of the authors.

    I wonder, how such fraudulent data should be dealt with short of not including in the MSS or saying the data look suspicious and hence not quoted.

  2. Regenerative Sciences welcomes the lawsuit the FDA has brought against them. As a terminally ill patient, I do too. The court must step in and decide if the FDA has overstepped its regulatory powers by declaring our own stem cells to be drugs. They have no legal authority to interfere with the practice of medicine. This lawsuit will have enormous consequences for doctors and the way they treat patients if the FDA wins. I do not want a regulatory agency deciding on my medical treatment. I want safe autologous stem cell therapy available in the U.S. NOW. I have had to go offshore to save my life. Others may not be able to do that. Autologous stem cell therapy is in use successfully all over the world. The U.S. has allowed itself to fall behind in the advancement of medicine by allowing the FDA to use its regulatory powers in a way that was never intended. I honestly don’t believe that anyone realizes how many terminally and chronically ill patients are being denied treatment with their own stem cells in this country. I also don’t believe that doctors are understanding the major implications this will have on their own practices whether they use stem cell therapy or not.

    • Dr RB Singh,MD says:

      The purpose of the FDA should be to justify that inappropriate treatment is not given to the
      people as well as see that the treatment should not be delayed to dying people. FDA should urgently send a team of researcher,s to this clinic to watch if the given treatment is providing relief to the people
      before asking the clinic to stop its operations. They should not behave like immigration
      officers on the airport who prevent the people to enter the United States without any reasion
      due to their whims.

    • Dr J Mehrishi, PhD, FRCPath says:

      To reassure this correspondent, sadly, autologous cells may well have the inherent genetic flaws that might well have led or contributed to the etiology of disease-pathology. Imagine a field full of the crop infected- some times it is best to get rid of the diseased plants, leaving no room for error and use fresh seeds. Therefore, to be on the safe side, plant new seeds, new progenitor cells- that is hematopoiesis to generate a new crop, set of cells.
      I hope that the correspondent might find this explanation helpful as the sole basis for isolating/fractionating of umbilical cord stem cells that we achieved in 1979 (Cambridge methods used in the lab of a French collaborator, who worked with me here and set up in Nancy/Paris). By 1989 Ted Boyse, Hal Broxmeyer and Eliane Gluckman (H

  3. Nirmal Kumar Mishra says:

    There are instances where relevant references have been deliberately omitted on the plea that the results contained in them were tentative. To cap it, the works of others were reproduced without mentioning their contribution.
    Referees did not bother about such omission, as they thought that the king cannot make any error. They (referees) were not unrepentant and even taunted the junior researchers, when pointed out. The publisher feigned ignorance. Such instances must be culled and action taken by some body or organization.

    Nirmal Kumar Mishra
    Retd. University Professor of Zoology, Patna University, Patna, India

  4. Nirmal Kumar Mishra says:

    There are instances where relevant references have been deliberately omitted on the plea that the results contained in them were tentative. To cap it, the works of others were reproduced without mentioning their contribution.
    Referees did not bother about such omission, as they thought that the king cannot make any error. They (referees) were unrepentant and even taunted the junior researchers, when pointed out. The publisher feigned ignorance. Such instances must be culled and action taken by some body or organization.
    Nirmal Kumar Mishra
    University Professor of Zoology, Patna University, Patna, India